Trial Profile

Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

12 Jul 2024 Planned End Date changed from 28 May 2024 to 28 May 2025.
08 Nov 2022 Planned End Date changed from 1 Sep 2022 to 28 May 2024.
12 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com